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The role of radiation therapy (RT) in the management of 
Hodgkin lymphoma (HL) and various non-Hodgkin lymphomas 
(NHL) has changed significantly over the last three decades. 
The indications, the fields and dose recommendations still 
continue to evolve. Old biases, new outcome data (often 
conflicting or controversial) as well as availability of tested 
and untested alternative drugs and a desire to evaluate them 
in an environment free of other high impact modalities have 
affected the consideration of radiotherapy in many tried and 
true indications for RT alone or as a combined-modality. 
Unfortunately many non-radiation oncologists were trained to 
believe that RT (even if limited and modernized) is loaded 
with long-term complications, while more chemotherapy, as 
an alternative is risk-free. Although radiotherapy remains, as 
stated by James Armitage, former ASCO president and highly 
regarded lymphoma leader, “the most effective single agent 
in the treatment of lymphomas”, the number of patients who 
are not receiving RT even when most guidelines recommend 
it has increased over the last two decades. Several 2014-2015 
publications documented it in analyzing tens of thousands of 
patients even in localized stages of common lymphomas. Two 
themes are repeating in analyses of SEER and the U.S. 
National Cancer Data Base (NCDB) in early-stage HL 
(lymphocyte predominant and classical HL), in early-stage 
follicular lymphomas, in early-stage diffuse large B-cell 
lymphomas (DLBCL), and primary mediastinal lymphomas: 1. 
The use of RT is decreasing; 2. Looking at overall survival in 
multivariate analysis and using propensity scores- Not 
receiving RT is an independent factor associated with a 
significantly decreased overall survival. In an era of 
individualized medicine, one approach or dogmatic concepts 
without understanding what the other modality may offer 
your patient does not reflect best care. As radiation 
oncologists we are often dependent on the “gate keepers” 
for consulting lymphoma patients and thus our responsibility 
is to remain up-to-date on the issues relevant to the use of 
RT, the arguments and the studies for RT exclusion or 
inclusion, and to inform our colleagues and our patients of 
what radiation may offer in terms of outcome and avoidance 
of toxicity. This session will review the controversial issues of 
the main indications for using RT in lymphoma, mostly in 
early-stages of HL, DLBCL, and indolent lymphomas. 
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The role of radiotherapy (RT) in the treatment of lymphomas 
has changed from being the primary treatment. In most 
situations RT is now part of a combined modality strategy, as 
consolidary treatment after primary chemotherapy or 
immunochemotherapy. With modern effective systemic 
treatments, microscopic disease is efficiently managed, and 
RT is only needed to treat initial macroscopic disease or 
residual masses. Moreover, the long-term follow-up of 
patients treated in the past with extended field RT has 
demonstrated serious long-term sequelae from the fairly low 
doses which used to be considered safe. With modern RT for 
lymphomas only the initially macroscopically involved sites or 
residual masses are irradiated to the lowest doses necessary 
for optimal tumour control, and the utmost care is taken to 
irradiate as little as possible of the surrounding normal 
tissues, thus minimizing the risk of long term complications.  
Modern advanced imaging allows a precise delineation of the 
involved lymph nodes, and techniques such as image fusion 
and deformable co-registration allow transfer of target 
volumes from pre-chemotherapy to post-chemotherapy 
images for treatment planning. The majority of lymphomas 
are FDG-avid, and PET/CT-scans for treatment planning are 
highly recommended. Modern highly conformal planning and 
treatment techniques, combined in many situations with 
even lower RT doses, have further reduced the radiation 
doses to normal tissues. In the past 15 years there has been a 
veritable paradigm shift in lymphoma RT, from 2-dimensional 
treatment planning and RT to regions defined by bony 
landmarks, to 3-dimensional treatment planning and RT to 
volumes defined by advanced imaging and conforming to the 
ICRU guidelines, similar to the principles of modern RT of 
solid tumours. Guidelines for modern radiotherapy of Hodgkin 
lymphoma, nodal lymphomas, extranodal lymphomas, 
cutaneous lymphomas, and pediatric lymphomas have been 
published by the International Lymphoma Radiation Oncology 
Group (IROG), and they have been implemented by most 
large centres and cooperative groups worldwide. The new 
concept of involved site radiation therapy (ISRT) takes into 
account different scenarios with regard to the quality of pre-
chemotherapy imaging, where optimal imaging allowing 
image fusion allows for RT to the smallest volumes. In other 
situations somewhat larger margins may be needed to allow 
for uncertainties in contouring, but the volumes irradiated 
are still much smaller than in the past.  
Estimates of the consequences on long-term toxicity of these 
modern treatments demonstrate very significant reductions 
in the risks of second malignancies, cardiovascular disease 
and other long-term sequelae compared to what has been 
seen after the extended treatment fields of the past. It is 
important to realize that these treatments are now obsolete, 
and that the analyses of long-term sequelae of RT for 
lymphomas from the era of the extended fields, which have 
been extensively published, are not directly relevant for 
patients treated with modern highly conformal RT.  
More than 60 different lymphoma diseases have now been 
defined, and lymphomas may present in all parts of the body, 
both within and outside of the lymphatic system. Hence, 
there is great variation in target volumes and critical normal 
structures from patient to patient. With highly conformal 
treatments such as intensity modulated radiotherapy (IMRT) 
or volumetric arc therapy there are many possible variations 
which may be used in different patients to optimize 
treatment. An “intelligent” choice of treatment angles for 
IMRT may allow sparing of particular organs at risk. 
Treatment of mediastinal or upper abdominal lymphomas in 
deep inspiration breath hold allows significant sparing of the 
heart and lungs. Which technique should be used in different 
patients will depend on the location of the target and 
considerations of the importance of different toxicities in 
relation to age, gender, comorbidities, and risk factors for 
other diseases.  
Dose constraints normally used for solid tumour radiotherapy 
are not optimal for lymphoma RT, as most of the 
conventional dose constraints for different organs are higher 
than the RT doses prescribed for lymphomas. Hence, if 
conventional dose constraints are used uncritically, most 
plans will be within the limits, even if far from the best plan 
achievable. Doses to all normal structures should be kept as 
low as possible. However, combining dose-response data for 
all relevant normal structures and using mathematical 
modeling to predict long-term risks of relevant sequelae 
would allow for a quantitative comparison of different 
treatment plans in individual patients. Developing a tool for 
this kind of multispectral plan evaluation would enable 
further optimization of RT for lymphomas in the future. 
 
 
 
 
 
 
 
